Emerging ADCs and Their Role in Advanced Lung Cancer Treatment
Webinar | English | 2023 | 60 Min
Image For Activity Cover
Credit Offered
1 ACCME Credit
1 Certificate of Attendance Credit
Antibody drug conjugates are novel agents developed for the treatment of a variety of cancers, including lung cancer. This webinar describes the mechanism of action of these agents and will inform the audience of the current use and areas of development. Since these agents are very novel, it is important to discuss the unique side effects associated with treatment and the management of these unique toxicities. Brought to you by IASLC’s Education Committee.
Live Activity Date: August 23, 2023
Enduring Activity Launch Date: December 19, 2023
Enduring Activity Expiration Date: December 18, 2024
Physicians, nurses, allied health professionals, and researchers.
Upon completion of this activity, the participants should be able to: 
  • Describe and understand the mechanism of action of ADC.
  • Identify drugs in development and indications.
  • Differentiate drug related adverse events and management of side effects.
  • Antoinette Wozniak, MD, Lung Cancer Research Foundation, University of Pittsburgh, Pittsburgh, PA, USA
  • Alona Zer, MD, Rambam Health Care Campus, Haifa, Israel
  • Daniel Tan, MD, BSc, MBBS, MRCP, National Cancer Centre, Singapore
  • Benjamin Levy, MD, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name Commercial Interest Role Level of Participation in the Activity
Antoinette Wozniak EPIC Pharma Speaker Planner/Moderator
  OncLive/MJH Life Sciences Speaker  
  Daiichi-Sankyo Consultant  
Daniel Tan AstraZeneca Consultant/Research Funding Planner/Speaker
  Pfizer Research Funding  
  ACM Biolabs Research Funding  
  Amgen Consultant/Research Funding  
  Pfizer Consultant  
  Novartis Consultant  
  Takeda Consultant  
  Bayer Consultant  
  DKSH Indonesia Consultant  
  Roche Consultant  
  GSK Consultant  
  C2i Genomics Stock/Stock Options  
  AIMIL Pharmaceuticals Stock/Stock Options  
  Oncoshot Stock/Stock Options  
Benjamin Levy AstraZeneca Consultant Planner/Speaker
  Daiichi Sankyo Consultant  
  Janssen Pharmaceuticals Consultant  
  Eli Lilly Consultant  
  Merck Consultant  
  Genentech/Roche Consultant  
  Novartis Consultant  
  Amgen Consultant  
  Takeda Pharmaceuticals Consultant  
  Pfizer Consultant  
Alona Zer AstraZeneca Advisor Planner/Speaker
  Roche Research Funding  
  MSD Research Funding  
  XAIR/Beyond Air Consultant  
  Takeda Pharmaceuticals Advisor  

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

The International Association for the Study of Lung Cancer designates the enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

International CPD Credit Reciprocity Agreements

The Royal College will recognize the number of participation hours as MOC Program Section 1 accredited group learning credits for group learning activities developed by Accreditation Council for Continuing Medical Education (ACCME)-accredited physician organizations (university, academy, specialty society, hospital department etc.) that are held within and outside of Canada. Agreement dates: November 1, 2019 to December 31, 2025.

European Union
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

The American Medical Association (AMA) and the Department of Healthcare Professions–Accreditation Section (DHP-AS), Ministry of Public Health–Qatar have renewed their CME agreement under which select activities approved for AMA PRA Category 1 Credit™ are eligible for conversion of the hours of participation to Department of Healthcare Professions Continuing Professional Development (DHP-CPD) credit. This agreement is in place through Dec. 31, 2026.
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:
  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out, if applicable.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.
  4. Complete the activity evaluation to provide feedback for future programming and receive credit.
You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.
If you need assistance with this activity, please email: education@iaslc.org.
Powered By